APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anti-Obesity Prescription

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Anti-Obesity Prescription Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173965280322 December 2025188 pages

Choose your research edition.

Industry ResearchAnti-Obesity Prescription Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Obesity Prescription Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Anti-Obesity Prescription Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Obesity Prescription Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Obesity Prescription Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Anti-Obesity Prescription market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Anti-Obesity Prescription is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-Obesity Prescription is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Obesity Prescription is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Anti-Obesity Prescription is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anti-Obesity Prescription include Akrimax Pharmaceuticals, Alpex Pharma, Arena Pharmaceuticals, Arrowhead Research, Bridge BioResearch, Compellis Pharmaceuticals, Yungjin Pharm, Zealand Pharma and Zydus Cadila, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-Obesity Prescription market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Obesity Prescription and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Obesity Prescription sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Obesity Prescription market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-Obesity Prescription Segment by Company

Akrimax Pharmaceuticals

Alpex Pharma

Arena Pharmaceuticals

Arrowhead Research

Bridge BioResearch

Compellis Pharmaceuticals

Yungjin Pharm

Zealand Pharma

Zydus Cadila

Anti-Obesity Prescription Segment by Type

Lorcaserin

Liraglutide

Phentermine and Topiramate

Orlistat

Bupropion and Naltrexone

Anti-Obesity Prescription Segment by Application

E-Commerce

Retail Pharmacies

Hospital Pharmacies

Anti-Obesity Prescription Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Prescription market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Prescription and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Prescription.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-Obesity Prescription market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anti-Obesity Prescription manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Anti-Obesity Prescription in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Anti-Obesity Prescription in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Anti-Obesity Prescription Industry Trends Table 2. Anti-Obesity Prescription Industry Drivers Table 3. Anti-Obesity Prescription Industry Opportunities and Challenges Table 4. Anti-Obesity Prescription Industry Restraints Table 5. Global Anti-Obesity Prescription Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Anti-Obesity Prescription Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Anti-Obesity Prescription Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Anti-Obesity Prescription Sales Market Share by Manufacturers Table 9. Global Anti-Obesity Prescription Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Anti-Obesity Prescription Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Anti-Obesity Prescription Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Anti-Obesity Prescription Manufacturers, Product Type & Application Table 13. Global Anti-Obesity Prescription Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-Obesity Prescription by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Lorcaserin Table 17. Major Manufacturers of Liraglutide Table 18. Major Manufacturers of Phentermine and Topiramate Table 19. Major Manufacturers of Orlistat Table 20. Major Manufacturers of Bupropion and Naltrexone Table 21. Global Anti-Obesity Prescription Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Anti-Obesity Prescription Sales by Type (2021-2026) & (k units) Table 23. Global Anti-Obesity Prescription Sales by Type (2027-2032) & (k units) Table 24. Global Anti-Obesity Prescription Sales Market Share by Type (2021-2026) Table 25. Global Anti-Obesity Prescription Sales Market Share by Type (2027-2032) Table 26. Global Anti-Obesity Prescription Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Anti-Obesity Prescription Revenue by Type (2021-2026) & (k units) Table 28. Global Anti-Obesity Prescription Revenue by Type (2027-2032) & (k units) Table 29. Global Anti-Obesity Prescription Revenue Market Share by Type (2021-2026) Table 30. Global Anti-Obesity Prescription Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of E-Commerce Table 32. Major Manufacturers of Retail Pharmacies Table 33. Major Manufacturers of Hospital Pharmacies Table 34. Global Anti-Obesity Prescription Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Anti-Obesity Prescription Sales by Application (2021-2026) & (k units) Table 36. Global Anti-Obesity Prescription Sales by Application (2027-2032) & (k units) Table 37. Global Anti-Obesity Prescription Sales Market Share by Application (2021-2026) Table 38. Global Anti-Obesity Prescription Sales Market Share by Application (2027-2032) Table 39. Global Anti-Obesity Prescription Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Anti-Obesity Prescription Revenue by Application (2021-2026) & (k units) Table 41. Global Anti-Obesity Prescription Revenue by Application (2027-2032) & (k units) Table 42. Global Anti-Obesity Prescription Revenue Market Share by Application (2021-2026) Table 43. Global Anti-Obesity Prescription Revenue Market Share by Application (2027-2032) Table 44. Global Anti-Obesity Prescription Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Anti-Obesity Prescription Sales by Region (2021-2026) & (k units) Table 46. Global Anti-Obesity Prescription Sales Market Share by Region (2021-2026) Table 47. Global Anti-Obesity Prescription Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global Anti-Obesity Prescription Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Anti-Obesity Prescription Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America Anti-Obesity Prescription Sales by Country (2021-2026) & (k units) Table 51. North America Anti-Obesity Prescription Sales by Country (2027-2032) & (k units) Table 52. Europe Anti-Obesity Prescription Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe Anti-Obesity Prescription Sales by Country (2021-2026) & (k units) Table 54. Europe Anti-Obesity Prescription Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific Anti-Obesity Prescription Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific Anti-Obesity Prescription Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific Anti-Obesity Prescription Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa Anti-Obesity Prescription Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa Anti-Obesity Prescription Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa Anti-Obesity Prescription Sales by Country (2027-2032) & (k units) Table 61. Global Anti-Obesity Prescription Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Anti-Obesity Prescription Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Anti-Obesity Prescription Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Anti-Obesity Prescription Revenue Market Share by Region (2021-2026) Table 65. Global Anti-Obesity Prescription Revenue Market Share by Region (2027-2032) Table 66. Akrimax Pharmaceuticals Company Information Table 67. Akrimax Pharmaceuticals Business Overview Table 68. Akrimax Pharmaceuticals Anti-Obesity Prescription Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Akrimax Pharmaceuticals Anti-Obesity Prescription Product Portfolio Table 70. Akrimax Pharmaceuticals Recent Development Table 71. Alpex Pharma Company Information Table 72. Alpex Pharma Business Overview Table 73. Alpex Pharma Anti-Obesity Prescription Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Alpex Pharma Anti-Obesity Prescription Product Portfolio Table 75. Alpex Pharma Recent Development Table 76. Arena Pharmaceuticals Company Information Table 77. Arena Pharmaceuticals Business Overview Table 78. Arena Pharmaceuticals Anti-Obesity Prescription Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Arena Pharmaceuticals Anti-Obesity Prescription Product Portfolio Table 80. Arena Pharmaceuticals Recent Development Table 81. Arrowhead Research Company Information Table 82. Arrowhead Research Business Overview Table 83. Arrowhead Research Anti-Obesity Prescription Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Arrowhead Research Anti-Obesity Prescription Product Portfolio Table 85. Arrowhead Research Recent Development Table 86. Bridge BioResearch Company Information Table 87. Bridge BioResearch Business Overview Table 88. Bridge BioResearch Anti-Obesity Prescription Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Bridge BioResearch Anti-Obesity Prescription Product Portfolio Table 90. Bridge BioResearch Recent Development Table 91. Compellis Pharmaceuticals Company Information Table 92. Compellis Pharmaceuticals Business Overview Table 93. Compellis Pharmaceuticals Anti-Obesity Prescription Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Compellis Pharmaceuticals Anti-Obesity Prescription Product Portfolio Table 95. Compellis Pharmaceuticals Recent Development Table 96. Yungjin Pharm Company Information Table 97. Yungjin Pharm Business Overview Table 98. Yungjin Pharm Anti-Obesity Prescription Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Yungjin Pharm Anti-Obesity Prescription Product Portfolio Table 100. Yungjin Pharm Recent Development Table 101. Zealand Pharma Company Information Table 102. Zealand Pharma Business Overview Table 103. Zealand Pharma Anti-Obesity Prescription Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Zealand Pharma Anti-Obesity Prescription Product Portfolio Table 105. Zealand Pharma Recent Development Table 106. Zydus Cadila Company Information Table 107. Zydus Cadila Business Overview Table 108. Zydus Cadila Anti-Obesity Prescription Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Zydus Cadila Anti-Obesity Prescription Product Portfolio Table 110. Zydus Cadila Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Anti-Obesity Prescription Distributors List Table 114. Anti-Obesity Prescription Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Anti-Obesity Prescription Product Image Figure 2. Global Anti-Obesity Prescription Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Obesity Prescription Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-Obesity Prescription Sales (2021-2032) & (k units) Figure 5. Global Anti-Obesity Prescription Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Anti-Obesity Prescription Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Lorcaserin Image Figure 9. Liraglutide Image Figure 10. Phentermine and Topiramate Image Figure 11. Orlistat Image Figure 12. Bupropion and Naltrexone Image Figure 13. Global Anti-Obesity Prescription Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Anti-Obesity Prescription Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Anti-Obesity Prescription Sales Market Share by Type (2021-2032) Figure 16. Global Anti-Obesity Prescription Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Anti-Obesity Prescription Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Anti-Obesity Prescription Revenue Market Share by Type (2021-2032) Figure 19. E-Commerce Image Figure 20. Retail Pharmacies Image Figure 21. Hospital Pharmacies Image Figure 22. Global Anti-Obesity Prescription Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Anti-Obesity Prescription Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Anti-Obesity Prescription Sales Market Share by Application (2021-2032) Figure 25. Global Anti-Obesity Prescription Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Anti-Obesity Prescription Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Anti-Obesity Prescription Revenue Market Share by Application (2021-2032) Figure 28. North America Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America Anti-Obesity Prescription Sales Market Share by Country (2021-2032) Figure 30. U.S. Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Anti-Obesity Prescription Sales Market Share by Country (2021-2032) Figure 35. Germany Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 36. France Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Anti-Obesity Prescription Sales Market Share by Country (2021-2032) Figure 42. China Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 46. India Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Anti-Obesity Prescription Sales Market Share by Country (2021-2032) Figure 50. Brazil Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile Anti-Obesity Prescription Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global Anti-Obesity Prescription Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Anti-Obesity Prescription Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Figure 61. North America Anti-Obesity Prescription Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Figure 63. Europe Anti-Obesity Prescription Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Anti-Obesity Prescription Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Anti-Obesity Prescription Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Anti-Obesity Prescription Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Anti-Obesity Prescription Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Lorcaserin
  • Liraglutide
  • Phentermine and Topiramate
  • Orlistat
  • Bupropion and Naltrexone
Applications
  • E-Commerce
  • Retail Pharmacies
  • Hospital Pharmacies
Companies covered
  • Akrimax Pharmaceuticals
  • Alpex Pharma
  • Arena Pharmaceuticals
  • Arrowhead Research
  • Bridge BioResearch
  • Compellis Pharmaceuticals
  • Yungjin Pharm
  • Zealand Pharma
  • Zydus Cadila

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-Obesity Prescription Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-Obesity Prescription Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Anti-Obesity Prescription Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Anti-Obesity Prescription Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Anti-Obesity Prescription Market Dynamics
  1. 2.1 Anti-Obesity Prescription Industry Trends
  2. 2.2 Anti-Obesity Prescription Industry Drivers
  3. 2.3 Anti-Obesity Prescription Industry Opportunities and Challenges
  4. 2.4 Anti-Obesity Prescription Industry Restraints
3 Anti-Obesity Prescription Market by Manufacturers
  1. 3.1 Global Anti-Obesity Prescription Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Anti-Obesity Prescription Sales by Manufacturers (2021-2026)
  3. 3.3 Global Anti-Obesity Prescription Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Anti-Obesity Prescription Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anti-Obesity Prescription Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Anti-Obesity Prescription Manufacturers, Product Type & Application
  7. 3.7 Global Anti-Obesity Prescription Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anti-Obesity Prescription Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anti-Obesity Prescription Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anti-Obesity Prescription Tier 1, Tier 2, and Tier 3
4 Anti-Obesity Prescription Market by Type
  1. 4.1 Anti-Obesity Prescription Type Introduction
  2. 4.1.1 Lorcaserin
  3. 4.1.2 Liraglutide
  4. 4.1.3 Phentermine and Topiramate
  5. 4.1.4 Orlistat
  6. 4.1.5 Bupropion and Naltrexone
  7. 4.2 Global Anti-Obesity Prescription Sales by Type
  8. 4.2.1 Global Anti-Obesity Prescription Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Anti-Obesity Prescription Sales by Type (2021-2032)
  10. 4.2.3 Global Anti-Obesity Prescription Sales Market Share by Type (2021-2032)
  11. 4.3 Global Anti-Obesity Prescription Revenue by Type
  12. 4.3.1 Global Anti-Obesity Prescription Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Anti-Obesity Prescription Revenue by Type (2021-2032)
  14. 4.3.3 Global Anti-Obesity Prescription Revenue Market Share by Type (2021-2032)
5 Anti-Obesity Prescription Market by Application
  1. 5.1 Anti-Obesity Prescription Application Introduction
  2. 5.1.1 E-Commerce
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Anti-Obesity Prescription Sales by Application
  6. 5.2.1 Global Anti-Obesity Prescription Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-Obesity Prescription Sales by Application (2021-2032)
  8. 5.2.3 Global Anti-Obesity Prescription Sales Market Share by Application (2021-2032)
  9. 5.3 Global Anti-Obesity Prescription Revenue by Application
  10. 5.3.1 Global Anti-Obesity Prescription Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Anti-Obesity Prescription Revenue by Application (2021-2032)
  12. 5.3.3 Global Anti-Obesity Prescription Revenue Market Share by Application (2021-2032)
6 Global Anti-Obesity Prescription Sales by Region
  1. 6.1 Global Anti-Obesity Prescription Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Obesity Prescription Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-Obesity Prescription Sales by Region (2021-2026)
  4. 6.2.2 Global Anti-Obesity Prescription Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-Obesity Prescription Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Anti-Obesity Prescription Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Anti-Obesity Prescription Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Anti-Obesity Prescription Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Anti-Obesity Prescription Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Anti-Obesity Prescription Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Anti-Obesity Prescription Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Anti-Obesity Prescription Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Anti-Obesity Prescription Revenue by Region
  1. 7.1 Global Anti-Obesity Prescription Revenue by Region
  2. 7.1.1 Global Anti-Obesity Prescription Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Anti-Obesity Prescription Revenue by Region (2021-2026)
  4. 7.1.3 Global Anti-Obesity Prescription Revenue by Region (2027-2032)
  5. 7.1.4 Global Anti-Obesity Prescription Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Anti-Obesity Prescription Revenue (2021-2032)
  8. 7.2.2 North America Anti-Obesity Prescription Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Anti-Obesity Prescription Revenue (2021-2032)
  11. 7.3.2 Europe Anti-Obesity Prescription Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Anti-Obesity Prescription Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Anti-Obesity Prescription Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Anti-Obesity Prescription Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Anti-Obesity Prescription Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Akrimax Pharmaceuticals
  2. 8.1.1 Akrimax Pharmaceuticals Company Information
  3. 8.1.2 Akrimax Pharmaceuticals Business Overview
  4. 8.1.3 Akrimax Pharmaceuticals Anti-Obesity Prescription Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Akrimax Pharmaceuticals Anti-Obesity Prescription Product Portfolio
  6. 8.1.5 Akrimax Pharmaceuticals Recent Developments
  7. 8.2 Alpex Pharma
  8. 8.2.1 Alpex Pharma Company Information
  9. 8.2.2 Alpex Pharma Business Overview
  10. 8.2.3 Alpex Pharma Anti-Obesity Prescription Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Alpex Pharma Anti-Obesity Prescription Product Portfolio
  12. 8.2.5 Alpex Pharma Recent Developments
  13. 8.3 Arena Pharmaceuticals
  14. 8.3.1 Arena Pharmaceuticals Company Information
  15. 8.3.2 Arena Pharmaceuticals Business Overview
  16. 8.3.3 Arena Pharmaceuticals Anti-Obesity Prescription Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Arena Pharmaceuticals Anti-Obesity Prescription Product Portfolio
  18. 8.3.5 Arena Pharmaceuticals Recent Developments
  19. 8.4 Arrowhead Research
  20. 8.4.1 Arrowhead Research Company Information
  21. 8.4.2 Arrowhead Research Business Overview
  22. 8.4.3 Arrowhead Research Anti-Obesity Prescription Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Arrowhead Research Anti-Obesity Prescription Product Portfolio
  24. 8.4.5 Arrowhead Research Recent Developments
  25. 8.5 Bridge BioResearch
  26. 8.5.1 Bridge BioResearch Company Information
  27. 8.5.2 Bridge BioResearch Business Overview
  28. 8.5.3 Bridge BioResearch Anti-Obesity Prescription Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bridge BioResearch Anti-Obesity Prescription Product Portfolio
  30. 8.5.5 Bridge BioResearch Recent Developments
  31. 8.6 Compellis Pharmaceuticals
  32. 8.6.1 Compellis Pharmaceuticals Company Information
  33. 8.6.2 Compellis Pharmaceuticals Business Overview
  34. 8.6.3 Compellis Pharmaceuticals Anti-Obesity Prescription Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Compellis Pharmaceuticals Anti-Obesity Prescription Product Portfolio
  36. 8.6.5 Compellis Pharmaceuticals Recent Developments
  37. 8.7 Yungjin Pharm
  38. 8.7.1 Yungjin Pharm Company Information
  39. 8.7.2 Yungjin Pharm Business Overview
  40. 8.7.3 Yungjin Pharm Anti-Obesity Prescription Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Yungjin Pharm Anti-Obesity Prescription Product Portfolio
  42. 8.7.5 Yungjin Pharm Recent Developments
  43. 8.8 Zealand Pharma
  44. 8.8.1 Zealand Pharma Company Information
  45. 8.8.2 Zealand Pharma Business Overview
  46. 8.8.3 Zealand Pharma Anti-Obesity Prescription Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Zealand Pharma Anti-Obesity Prescription Product Portfolio
  48. 8.8.5 Zealand Pharma Recent Developments
  49. 8.9 Zydus Cadila
  50. 8.9.1 Zydus Cadila Company Information
  51. 8.9.2 Zydus Cadila Business Overview
  52. 8.9.3 Zydus Cadila Anti-Obesity Prescription Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Zydus Cadila Anti-Obesity Prescription Product Portfolio
  54. 8.9.5 Zydus Cadila Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-Obesity Prescription Value Chain Analysis
  2. 9.1.1 Anti-Obesity Prescription Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-Obesity Prescription Production Mode & Process
  6. 9.2 Anti-Obesity Prescription Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-Obesity Prescription Distributors
  9. 9.2.3 Anti-Obesity Prescription Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst